BACKGROUND: The prevalence of earlier stage chronic kidney disease is lower for African Americans than whites in the United States. This is counterintuitive given the known 4-fold greater incidence of end-stage renal disease (ESRD) in African Americans. We describe racial differences in the rate of progression to ESRD and address the competing risk of mortality. STUDY DESIGN: Retrospective analysis of Cooperative Cardiovascular Project data. SETTING & PARTICIPANTS: 127,736 Medicare beneficiaries 65 years and older admitted to 4,545 hospitals with acute myocardial infarction between February 1994 and June 1995, with follow-up data for ESRD and mortality through June 2004. PREDICTORS: African American versus white race, estimated glomerular filtration rate (eGFR), and their interaction; other characteristics at hospital admission. OUTCOMES & MEASUREMENTS: Time to ESRD using Cox proportional hazards models. RESULTS: Mean age was 77.1 years, with 8,278 African Americans (6.5%) and 49.9% women. Mean baseline eGFRs were 61.4 +/- 31.4 and 57.0 +/- 25.6 mL/min/1.73 m(2) (P < 0.001) for African Americans and whites, respectively. Of 2,161 patients (1.7%) progressing to ESRD (incidence, 3.75/1,000 person-years), 14.9% were African American. The adjusted hazard ratio for ESRD (African Americans versus whites) was 1.90 (95% confidence interval, 1.78 to 2.03); African Americans were at significantly increased risk of incident ESRD at each baseline eGFR stage (P for interaction < 0.001). Racial differences in incident ESRD were not accounted for by differences in mortality. LIMITATIONS: Retrospective analysis, residual bias from unmeasured factors, baseline eGFR determined from serum creatinine levels at the time of acute hospitalization. CONCLUSIONS: Within a nationally representative sample of Medicare patients with acute myocardial infarction, African Americans had an increased 10-year risk of ESRD regardless of baseline kidney function that was not accounted for by differences in pre-ESRD mortality.
BACKGROUND: The prevalence of earlier stage chronic kidney disease is lower for African Americans than whites in the United States. This is counterintuitive given the known 4-fold greater incidence of end-stage renal disease (ESRD) in African Americans. We describe racial differences in the rate of progression to ESRD and address the competing risk of mortality. STUDY DESIGN: Retrospective analysis of Cooperative Cardiovascular Project data. SETTING & PARTICIPANTS: 127,736 Medicare beneficiaries 65 years and older admitted to 4,545 hospitals with acute myocardial infarction between February 1994 and June 1995, with follow-up data for ESRD and mortality through June 2004. PREDICTORS: African American versus white race, estimated glomerular filtration rate (eGFR), and their interaction; other characteristics at hospital admission. OUTCOMES & MEASUREMENTS: Time to ESRD using Cox proportional hazards models. RESULTS: Mean age was 77.1 years, with 8,278 African Americans (6.5%) and 49.9% women. Mean baseline eGFRs were 61.4 +/- 31.4 and 57.0 +/- 25.6 mL/min/1.73 m(2) (P < 0.001) for African Americans and whites, respectively. Of 2,161 patients (1.7%) progressing to ESRD (incidence, 3.75/1,000 person-years), 14.9% were African American. The adjusted hazard ratio for ESRD (African Americans versus whites) was 1.90 (95% confidence interval, 1.78 to 2.03); African Americans were at significantly increased risk of incident ESRD at each baseline eGFR stage (P for interaction < 0.001). Racial differences in incident ESRD were not accounted for by differences in mortality. LIMITATIONS: Retrospective analysis, residual bias from unmeasured factors, baseline eGFR determined from serum creatinine levels at the time of acute hospitalization. CONCLUSIONS: Within a nationally representative sample of Medicare patients with acute myocardial infarction, African Americans had an increased 10-year risk of ESRD regardless of baseline kidney function that was not accounted for by differences in pre-ESRD mortality.
Authors: Paul Muntner; Britt Newsome; Holly Kramer; Carmen A Peralta; Yongin Kim; David R Jacobs; Catarina I Kiefe; Cora E Lewis Journal: Clin J Am Soc Nephrol Date: 2011-11-10 Impact factor: 8.237
Authors: Tahira P Alves; Xuelei Wang; Jackson T Wright; Lawrence J Appel; Tom Greene; Keith Norris; Julia Lewis Journal: J Am Soc Nephrol Date: 2010-07-22 Impact factor: 10.121
Authors: Tessa O van den Beukel; Moniek C M de Goeij; Friedo W Dekker; Carl E H Siegert; Nynke Halbesma Journal: Clin J Am Soc Nephrol Date: 2013-07-11 Impact factor: 8.237
Authors: Kiraat D Munshi; Ya-Chen T Shih; Lawrence M Brown; Samuel Dagogo-Jack; Jim Y Wan; Junling Wang Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2013-04 Impact factor: 2.217
Authors: Morgan E Grams; Josef Coresh; Dorry L Segev; Lauren M Kucirka; Hocine Tighiouart; Mark J Sarnak Journal: Clin J Am Soc Nephrol Date: 2012-08-02 Impact factor: 8.237
Authors: Talar W Markossian; Holly J Kramer; Nicholas J Burge; Ivan V Pacold; David J Leehey; Zhiping Huo; Julia Schneider; Benjamin Ling; Kevin T Stroupe Journal: Clin Kidney J Date: 2019-01-27
Authors: Laura Plantinga; Virginia J Howard; Suzanne Judd; Paul Muntner; Rikki Tanner; Dana Rizk; Daniel T Lackland; David G Warnock; George Howard; William M McClellan Journal: Int J Health Geogr Date: 2013-03-21 Impact factor: 3.918